Literature DB >> 32634830

Distinct Clinical Characteristics and Risk Factors for Mortality in Female Inpatients With Coronavirus Disease 2019 (COVID-19): A Sex-stratified, Large-scale Cohort Study in Wuhan, China.

Jing Chen1, Hualin Bai1, Jia Liu1, Ge Chen1, Qiuyue Liao1, Jie Yang1, Peng Wu1, Juncheng Wei1, Ding Ma1, Gang Chen1, Jihui Ai2, Kezhen Li1.   

Abstract

BACKGROUND: As the coronavirus disease 2019 (COVID-19) outbreak accelerates worldwide, it is important to evaluate sex-specific clinical characteristics and outcomes, which may affect public health policies.
METHODS: Patients with COVID-19 admitted to Tongji Hospital between 18 January and 27 March 2020 were evaluated. Clinical features, laboratory data, complications, and outcomes were compared between females and males. Risk factors for mortality in the whole population, females, and males were determined respectively.
RESULTS: There were 1667 (50.38%) females among the 3309 patients. The mortality rate was 5.9% in females but 12.7% in males. Compared with males, more females had no initial symptoms (11.1% vs 8.3%, P = .008). Complications including acute respiratory distress syndrome, acute kidney injury, septic shock, cardiac injury, and coagulation disorder were less common in females; critical illness was also significantly less common in females (31.1% vs 39.4%, P < .0001). Significantly fewer females received antibiotic treatment (P = .001), antiviral therapy (P = .025), glucocorticoids treatment (P < .0001), mechanical ventilation (P < .0001), and had intensive care unit admission (P < .0001). A lower risk of death was found in females (OR, .44; 95% CI, .34-.58) after adjusting for age and coexisting diseases. Among females, age, malignancy, chronic kidney disease, and days from onset to admission were significantly associated with mortality, while chronic kidney disease was not a risk factor in males.
CONCLUSIONS: Significantly milder illness and fewer deaths were found in female COVID-19 inpatients and risk factors associated with mortality varied among males and females.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; novel coronavirus; risk factors; sex

Year:  2020        PMID: 32634830      PMCID: PMC7454470          DOI: 10.1093/cid/ciaa920

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  22 in total

1.  In-hospital mortality in SARS-CoV-2 stratified by sex diffrences: A retrospective cross-sectional cohort study.

Authors:  Mohammed Al-Jarallah; Rajesh Rajan; Raja Dashti; Ahmad Al Saber; Peter A Brady; Hassan Abdelnaby; Moudhi Alroomi; Wael Aboelhassan; Mohammed Abdullah; Noor AlNasrallah; Bader Al-Bader; Haya Malhas; Maryam Ramadhan; Naser Alotaibi; Mohammad Al Saleh; Farah Almutairi; Kobalava D Zhanna
Journal:  Ann Med Surg (Lond)       Date:  2022-06-20

Review 2.  Heterogeneity and Risk of Bias in Studies Examining Risk Factors for Severe Illness and Death in COVID-19: A Systematic Review and Meta-Analysis.

Authors:  Abraham Degarege; Zaeema Naveed; Josiane Kabayundo; David Brett-Major
Journal:  Pathogens       Date:  2022-05-10

3.  Continued Virus-Specific Antibody-Secreting Cell Production, Avidity Maturation and B Cell Evolution in Patients Hospitalized with COVID-19.

Authors:  Maggie L Bartlett; San Suwanmanee; Nadine Peart Akindele; Shristi Ghimire; Andy K P Chan; Chenxu Guo; Stephen J Gould; Andrea L Cox; Diane E Griffin
Journal:  Viral Immunol       Date:  2022-03-14       Impact factor: 2.175

4.  Efficacy of baloxavir marboxil on household transmission of influenza infection.

Authors:  Takumi Umemura; Yoshikazu Mutoh; Takato Kawamura; Masayuki Saito; Takahito Mizuno; Aiko Ota; Koji Kozaki; Tetsuya Yamada; Yoshiaki Ikeda; Toshihiko Ichihara
Journal:  J Pharm Health Care Sci       Date:  2020-10-01

5.  Analyzing master regulators and scRNA-seq of COVID-19 patients reveals an underlying anti-SARS-CoV-2 mechanism of ZNF proteins.

Authors:  Shijie Qin; Weijun Xu; Canbiao Wang; Sizhu Jiang; Wei Dai; Yang Yang; Jiawei Shen; Ping Jin; Fei Ma; Xinyi Xia
Journal:  Brief Bioinform       Date:  2021-04-27       Impact factor: 11.622

6.  Sex Differences in the Incidence and Risk Factors of Myocardial Injury in COVID-19 Patients: A Retrospective Cohort Study.

Authors:  Ran Cheng; Chuan Liu; Jie Yang; Yuanqi Yang; Renzheng Chen; Xiaohan Ding; Xubin Gao; Jingbin Ke; Fangzhengyuan Yuan; Chunyan He; Yang Shen; Limin Zhang; Ping Li; Hu Tan; Lan Huang
Journal:  Front Physiol       Date:  2021-02-16       Impact factor: 4.566

7.  The Association of Cerebrovascular Disease with Adverse Outcomes in COVID-19 Patients: A Meta-Analysis Based on Adjusted Effect Estimates.

Authors:  Jie Xu; Wenwei Xiao; Xuan Liang; Peihua Zhang; Li Shi; Ying Wang; Yadong Wang; Haiyan Yang
Journal:  J Stroke Cerebrovasc Dis       Date:  2020-08-28       Impact factor: 2.136

Review 8.  Acute Kidney Injury in COVID-19: The Chinese Experience.

Authors:  Xizi Zheng; Youlu Zhao; Li Yang
Journal:  Semin Nephrol       Date:  2020-09-04       Impact factor: 5.299

9.  Gender Differences in COVID-19 Deceased Cases in Jahrom City, South of Iran.

Authors:  Fatemeh Rahmanian; Naser Hatami; Marzieh Haghbeen; Rahim Raoufi; Ali Reza Abbasi; Heshmatollah Shakeri; Poyan Keshavarz; Elham Rafie; Mehdi Chegin; Esmaeal Raeyat Doost; Samaneh Abiri; Navid Kalani; Mahdi Foroughian; Mohsen Ebrahimi
Journal:  Bull Emerg Trauma       Date:  2021-04

10.  Prevalence and Associated Risk Factors of Mortality Among COVID-19 Patients: A Meta-Analysis.

Authors:  Farha Musharrat Noor; Md Momin Islam
Journal:  J Community Health       Date:  2020-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.